Product Description
Mechanisms of Action: DPP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Phenomix
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes|Kidney Diseases|ST Elevation Myocardial Infarction
Phase 2: Myocardial Ischemia|ST Elevation Myocardial Infarction|Type 2 Diabetes|Pulmonary Fibrosis
Phase 1: Rheumatic Fever|Cardiovascular Infections|Sexually Transmitted Diseases|Rheumatic Heart Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05881382 |
HEAL-MI | P3 |
Unknown status |
ST Elevation Myocardial Infarction |
2025-09-01 |
2025-10-02 |
Primary Endpoints |
|
ACTRN12620001363976p |
A-LONG | P2 |
Not yet recruiting |
Pulmonary Fibrosis |
2024-01-01 |
|||
ACTRN12621000135819p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Cardiovascular Infections|Sexually Transmitted Diseases|Rheumatic Heart Disease|Rheumatic Fever |
2021-03-31 |
|||
NCT03486080 |
REC-DUT-002 | P2 |
Completed |
Myocardial Ischemia|ST Elevation Myocardial Infarction |
2021-02-26 |
2021-05-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2018-000916-75 |
REC-DUT-002 | P2 |
Terminated |
Myocardial Ischemia|ST Elevation Myocardial Infarction |
2021-02-25 |
2022-03-13 |
Treatments |
|
ACTRN12620000138987p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Osteoarthritis |
2020-09-02 |
|||
ACTRN12619000748112p |
EPOLUX | N/A |
Not yet recruiting |
Breastfeeding|Pregnancy Outcomes |
2019-09-30 |
|||
NCT00998686 |
PHX1149-PROT402 | P3 |
Terminated |
Type 2 Diabetes |
2011-10-01 |
2019-03-19 |
Treatments |
|
NCT00958269 |
PHX1149-PROT306 | P3 |
Terminated |
Type 2 Diabetes|Kidney Diseases |
2011-09-01 |
2019-03-18 |
Treatments |
|
NCT00865592 |
PHX1149-PROT300E | P3 |
Terminated |
Type 2 Diabetes |
2011-01-01 |
2019-03-18 |
Treatments |
|
NCT00850239 |
PHX1149-PROT302 | P3 |
Terminated |
Type 2 Diabetes |
2010-10-01 |
2019-03-18 |
Treatments |
|
2009-012598-37 |
2009-012598-37 | P3 |
Terminated |
Type 2 Diabetes |
2010-08-12 |
2022-03-13 |
Treatments |
|
NCT00970424 |
DUT-MD-304 | P3 |
Terminated |
Type 2 Diabetes |
2010-08-01 |
2019-03-19 |
||
NCT01089790 |
REDWOOD403 | P3 |
Terminated |
Type 2 Diabetes |
2010-08-01 |
2019-03-19 |
Treatments |
|
2009-012597-13 |
2009-012597-13 | P3 |
Terminated |
Type 2 Diabetes |
2010-07-23 |
2025-07-09 |
Treatments |
|
NCT00947557 |
DUT-MD-303 | P3 |
Terminated |
Type 2 Diabetes |
2010-07-01 |
2019-03-18 |
||
2008-008974-30 |
2008-008974-30 | P3 |
Terminated |
Type 2 Diabetes |
2010-06-25 |
2022-03-13 |
Treatments |
|
2009-012663-34 |
2009-012663-34 | P3 |
Terminated |
Type 2 Diabetes |
2010-06-25 |
2022-03-13 |
Treatments |
|
2009-017524-36 |
2009-017524-36 | P3 |
Completed |
Type 2 Diabetes |
2010-06-23 |
2025-06-30 |
Treatments |
|
2009-017266-23 |
2009-017266-23 | N/A |
Terminated |
Type 2 Diabetes |
2010-06-03 |
2022-03-13 |
Treatments |
|
2009-012213-22 |
2009-012213-22 | P3 |
Terminated |
Type 2 Diabetes |
2010-01-28 |
2022-03-13 |
Treatments |
|
NCT00690638 |
PHX1149-PROT301 | P3 |
Completed |
Type 2 Diabetes |
2010-01-01 |
2019-03-18 |
Treatments |
|
NCT01101945 |
PHX1149-PROT202E | P2 |
Terminated |
Type 2 Diabetes |
2010-01-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/01/2022 |
News Article |
Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design |
|
06/01/2022 |
News Article |
Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design |
|
05/23/2022 |
News Article |
Recardio's Positive Phase 2 Results Presented as Latebreaker at World Congress on Acute Heart Failure 2022 in Madrid |
|
05/23/2022 |
News Article |
Recardio's Positive Phase 2 Results Presented as Latebreaker at World Congress on Acute Heart Failure 2022 in Madrid |